Joint Injections: Corticosteroid and Hyaluronic Acid

Joint injections deliver therapeutic agents directly into a synovial joint space, bypassing systemic circulation to achieve localized effects on inflammation or lubrication. Two distinct pharmacological categories dominate clinical practice: corticosteroid injections, which suppress local inflammatory cascades, and hyaluronic acid (viscosupplementation) injections, which augment synovial fluid viscoelasticity. Understanding the differences between these modalities — their mechanisms, indications, regulatory status, and clinical boundaries — is essential context for anyone navigating rheumatology resources and treatment options.

Definition and scope

A joint injection is a procedure in which a needle is introduced into the intra-articular space under sterile technique, with or without image guidance, to deposit a pharmaceutical agent. The two primary injectable categories serve different therapeutic aims.

Corticosteroid injections use glucocorticoid compounds — triamcinolone acetonide, methylprednisolone acetate, and betamethasone being the most common formulations — to reduce synovial inflammation. These agents bind glucocorticoid receptors in synovial tissue, suppressing cytokine production, reducing vascular permeability, and dampening the activity of inflammatory cells.

Hyaluronic acid injections (also called viscosupplementation) introduce exogenous hyaluronate — a naturally occurring glycosaminoglycan — into the joint, principally the knee. The U.S. Food and Drug Administration (FDA) has cleared hyaluronic acid products such as Hyalgan, Synvisc, and Euflexxa as Class III medical devices under 21 CFR Part 880 for the treatment of knee osteoarthritis when patients have not responded adequately to conservative nonpharmacological therapy and simple analgesics.

The regulatory context for rheumatology is directly relevant here: corticosteroid injectable formulations fall under FDA drug regulation (New Drug Application pathway), while most hyaluronic acid products are regulated as devices, creating distinct post-market surveillance obligations and labeling requirements for each category.

How it works

Corticosteroid mechanism

1. Receptor binding: Glucocorticoids diffuse across cell membranes and bind cytosolic glucocorticoid receptors in synovial fibroblasts and immune cells.
2. Transcriptional suppression: The receptor-ligand complex translocates to the nucleus, suppressing pro-inflammatory transcription factors including NF-κB.
3. Cytokine reduction: Downstream synthesis of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) is reduced locally.
4. Vascular effect: Capillary permeability decreases, reducing synovial edema and joint effusion.
5. Onset and duration: Clinical effect typically begins within 24–48 hours. Duration varies by formulation and joint but is generally measured in weeks; triamcinolone acetonide suspensions are formulated to slow systemic absorption, prolonging local dwell time.

Hyaluronic acid mechanism

Osteoarthritic joints exhibit degraded synovial fluid with reduced molecular weight and viscoelasticity. Injected hyaluronate restores the fluid's shock-absorbing and lubricating properties. Higher molecular weight formulations (Synvisc, ~6 million Daltons) are proposed to have longer mechanical effect. The biological mechanism may also involve binding to CD44 receptors on chondrocytes, modulating pain signaling pathways, though the American College of Rheumatology (ACR) notes in its clinical guidance that evidence for disease-modifying properties remains limited. The ACR 2019 Osteoarthritis Guidelines conditionally recommend against the routine use of intra-articular hyaluronic acid for knee osteoarthritis, citing inconsistent evidence compared with corticosteroids.

Common scenarios

Corticosteroid injections are used across a broader range of joint conditions than hyaluronic acid. Common clinical scenarios include:

• Rheumatoid arthritis flares: A single inflamed joint — commonly the knee, wrist, or ankle — that is disproportionately active relative to systemic disease control may be injected to bridge the gap before systemic medication adjustments take effect.
• Gout and pseudogout: Intra-articular corticosteroid is an evidence-supported option when oral anti-inflammatory therapy is contraindicated, as noted in ACR guidelines for the management of gout.
• Osteoarthritis with effusion: Moderate-to-large knee effusions with documented osteoarthritis respond to aspiration combined with corticosteroid instillation; joint aspiration procedures are described separately at joint aspiration.
• Adhesive capsulitis (frozen shoulder): Glenohumeral corticosteroid injection is a standard component of early-stage management.
• Psoriatic arthritis flares: Monoarticular or oligoarticular flares, particularly of the knee or ankle, may receive intra-articular corticosteroid as an adjunct.

Hyaluronic acid injections are approved in the United States exclusively for knee osteoarthritis. Protocol courses range from 3 to 5 weekly injections depending on the specific product, though single-injection formulations (Gel-One, Monovisc) have received FDA clearance. The procedure is typically performed in an outpatient setting with image guidance — fluoroscopy or musculoskeletal ultrasound — recommended to ensure accurate intra-articular placement. Ultrasound-guided injection techniques fall within the competency domain described under musculoskeletal ultrasound certification.

Decision boundaries

Selecting between these two modalities — or determining that neither is appropriate — depends on diagnosis, joint location, prior treatment history, and patient-specific contraindications.

Absolute contraindications to either injection type include active local or systemic infection, bacteremia, overlying skin infection at the injection site, and suspected joint prosthesis infection. Relative contraindications include poorly controlled diabetes mellitus (corticosteroids elevate blood glucose), bleeding diathesis or anticoagulation without bridging plan, and hypersensitivity to avian proteins (relevant for some hyaluronic acid products derived from rooster combs, such as Synvisc, which carries an FDA-labeled warning for avian hypersensitivity).

The ACR and European League Against Rheumatism (EULAR) both publish disease-specific recommendations that address injection frequency and the safety threshold of cumulative corticosteroid exposure. EULAR recommendations caution against exceeding 3 corticosteroid injections per joint per year based on cartilage toxicity signals observed in preclinical and observational data, a principle that guides clinical scheduling even in the absence of a regulatory ceiling enforced by statute.

References

• U.S. Food and Drug Administration — 21 CFR Part 880 (Medical Devices)
• American College of Rheumatology — 2019 Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee
• American College of Rheumatology — 2020 Guideline for the Management of Gout
• European League Against Rheumatism (EULAR) — Recommendations and Guidelines
• U.S. Food and Drug Administration — Drug Approval Database (Drugs@FDA)
• National Institutes of Health MedlinePlus — Corticosteroid Injections

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)